Research Summary
Research Summary
06/20/2024

Anthony Calabro, MA

Anthony Calabro, MA
In the ILLUMINATE-C trial, patients with advanced primary hyperoxaluria type 1 and severe renal impairment treated with lumasiran showed decreased plasma oxalate and good safety profiles at 6 months and 12...
06/20/2024
Research Summary
Research Summary
05/24/2024

Anthony Calabro, MA

Anthony Calabro, MA
Oxalate nephropathy is a commonly underrecognized cause of chronic kidney disease and end-stage kidney disease with multiple etiologies, including primary hyperoxaluria, enteric hyperoxaluria, or ingestion...
05/24/2024
research summary
research summary
04/09/2024

Leigh Precopio

Leigh Precopio
Researchers examined a new manifestation of primary hyperoxaluria that has rarely been described in previous literature and reviewed best approaches to managing dental complications in this patient...
04/09/2024
research summary
research summary
03/12/2024

Leigh Precopio

Leigh Precopio
Primary hyperoxaluria type 1 is a rare disease that is frequently diagnosed late due to its similar clinical presentation to other types of kidney disease. To better understand the characteristics of...
03/12/2024
research summary
research summary
02/28/2024

Leigh Precopio

Leigh Precopio
Individuals with primary hyperoxaluria type 1 are at an increased risk of urinary stone disease, nephrocalcinosis, and chronic kidney disease due to increased hepatic oxalate production. Researchers...
02/28/2024
FDA ALERT
FDA ALERT
01/29/2024

Anthony Calabro, MA

Anthony Calabro, MA
The once-monthly RNA interference injection medication received FDA approval based on results from the phase II PHYOX2 clinical trial and phase III PHYOX3 extension study.
01/29/2024